COCP Cocrystal Pharma Inc

Cocrystal Pharma to Present at the April 2020 Virtual Investor Summit

Cocrystal Pharma to Present at the April 2020 Virtual Investor Summit

– Presentation with live audio webcast on Wednesday, April 22 at 11:00 AM ET, immediately followed by an interactive Q&A session –

BOTHELL, WA,, April 15, 2020 (GLOBE NEWSWIRE) -- . (NASDAQ: COCP), (“Cocrystal” or the “Company”), a clinical stage biotechnology company discovering and developing novel antiviral therapeutics, announced today that Dr. Gary Wilcox, Chairman and Chief Executive Officer of Cocrystal will present at the on Wednesday, April 22nd, 2020 at 11:00 AM ET.

A live of the presentation will be available on the page of the section of the Company’s website (). Immediately following the presentation, management will participate in an interactive Q&A session with interested parties, allowing participants to type in questions and receive live responses. A webcast replay will be available two hours following the live presentation and will be accessible for 30 days.



To schedule a one-on-one call with management, please contact the conference at and for more information, please visit .



About Virtual Investor Summit

The Virtual Investor Summit is an online platform that offers both public and private companies, across multiple industries the ability to stay active and engaged with the investment community. Our inaugural summit on April 22-23, 2020 will feature company webcast presentations followed by a virtual, interactive Q&A session, allowing participants to type in questions and receive live responses. Interested participants also have the ability to request one-on-one calls with a featured company. For more information, please visit .

About Cocrystal Pharma, Inc.

Cocrystal Pharma, Inc. is a clinical stage biotechnology company discovering and developing novel antiviral therapeutics that target the replication process of influenza viruses, hepatitis C viruses, noroviruses and coronaviruses. Cocrystal employs unique structure-based technologies and Nobel Prize winning expertise to create first- and best-in-class antiviral drugs. For further information about Cocrystal, please visit .

Investor and Media Contact:

JTC Team, LLC

(833) 475-8247

EN
15/04/2020

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Cocrystal Pharma Inc

 PRESS RELEASE

Cocrystal Pharma Reports Second Quarter 2025 Financial Results and Pro...

Cocrystal Pharma Reports Second Quarter 2025 Financial Results and Provides Updates on its Antiviral Drug-Development Programs Favorable CDI-988 Phase 1 safety and tolerability reported Challenge study with CDI-988 as a norovirus preventive and treatment planned later this year BOTHELL, Wash., Aug. 14, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: COCP) (“Cocrystal” or the “Company”) reports financial results for the three and six months ended June 30, 2025, and provides updates on its antiviral product pipeline, upcoming milestones and business activities. “Preparations are underway for a Phase 1...

 PRESS RELEASE

Cocrystal Pharma Presents Phase 1 Results for Pan-Viral Inhibitor CDI-...

Cocrystal Pharma Presents Phase 1 Results for Pan-Viral Inhibitor CDI-988 at Department of Defense Medical Conference All CDI-988 doses, ranging from 100 mg to 1200 mg, in the Phase 1 study were well toleratedCompany expects to initiate Phase 1b study with CDI-988 in norovirus-infected healthy subjects later this yearLack of approved norovirus treatments or vaccines creates critical unmet medical need BOTHELL, Wash., Aug. 05, 2025 (GLOBE NEWSWIRE) -- . (Nasdaq: COCP) announces the presentation of favorable safety and tolerability data from a randomized, double-blinded, placebo-controlled...

 PRESS RELEASE

Cocrystal Pharma to Present Data from Phase 1 Study of First-in-Class ...

Cocrystal Pharma to Present Data from Phase 1 Study of First-in-Class Norovirus Protease Inhibitor CDI-988 at the 9th International Calicivirus Conference BOTHELL, Wash., July 10, 2025 (GLOBE NEWSWIRE) -- . (Nasdaq: COCP) announces that its first-in-class pan-viral protease inhibitor CDI-988 has been selected for an oral presentation at the 9th International Calicivirus Conference being held September 7-11, 2025 in Banff, Alberta, Canada. Sam Lee, PhD, the Company’s President and co-CEO, will present “Oral Direct-Acting Antiviral CDI-988 for Norovirus Infection Prevention and Treatment: M...

 PRESS RELEASE

Cocrystal Pharma’s Novel Norovirus Antiviral to be Presented at Depart...

Cocrystal Pharma’s Novel Norovirus Antiviral to be Presented at Department of Defense Medical Conference BOTHELL, Wash., June 05, 2025 (GLOBE NEWSWIRE) -- . (Nasdaq: COCP) announces that its broad-spectrum protease inhibitor CDI-988 will be featured in an oral presentation at the 2025 Military Health System Research Symposium (MHSRS) being held August 4-7 in Kissimmee, Fla. Cocrystal is developing CDI-988 as a norovirus prophylaxis and treatment. Sam Lee, PhD, the Company’s President and co-CEO, will discuss Phase 1 results during the Broad-Spectrum Anti-Viral Countermeasures breakout ses...

 PRESS RELEASE

Cocrystal Pharma’s Investigational Drug Candidate CC-42344 Demonstrate...

Cocrystal Pharma’s Investigational Drug Candidate CC-42344 Demonstrates Strong Antiviral Potency Against the 2024 Highly Pathogenic H5N1 Avian Influenza Strain CC-42344 was shown to be highly active against the highly pathogenic 2024 Texas H5N1 avian influenza strain The Company’s virology study further confirmed the previous structural and in vitro data that revealed the binding of CC-42344 to PB2 protein of the 2024 H5N1 avian influenza virus BOTHELL, Wash., May 29, 2025 (GLOBE NEWSWIRE) -- . (Nasdaq: COCP) announces that a recent virology study showed its novel, broad-spectrum influe...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch